MyMD Pharmaceuticals (MYMD) Competitors $0.73 -0.15 (-17.28%) As of 02/3/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends MYMD vs. PMCB, CLRB, RLMD, TSBX, PRPH, PHXM, JAGX, AYTU, BCDA, and CSCIShould you be buying MyMD Pharmaceuticals stock or one of its competitors? The main competitors of MyMD Pharmaceuticals include PharmaCyte Biotech (PMCB), Cellectar Biosciences (CLRB), Relmada Therapeutics (RLMD), Turnstone Biologics (TSBX), ProPhase Labs (PRPH), PHAXIAM Therapeutics (PHXM), Jaguar Health (JAGX), Aytu BioPharma (AYTU), BioCardia (BCDA), and COSCIENS Biopharma (CSCI). These companies are all part of the "pharmaceutical products" industry. MyMD Pharmaceuticals vs. PharmaCyte Biotech Cellectar Biosciences Relmada Therapeutics Turnstone Biologics ProPhase Labs PHAXIAM Therapeutics Jaguar Health Aytu BioPharma BioCardia COSCIENS Biopharma PharmaCyte Biotech (NASDAQ:PMCB) and MyMD Pharmaceuticals (NASDAQ:MYMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, community ranking, media sentiment, analyst recommendations and institutional ownership. Does the MarketBeat Community favor PMCB or MYMD? PharmaCyte Biotech and MyMD Pharmaceuticals both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformPharmaCyte BiotechN/AN/AMyMD PharmaceuticalsN/AN/A Which has better valuation and earnings, PMCB or MYMD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharmaCyte BiotechN/AN/A$330K$0.532.91MyMD PharmaceuticalsN/AN/A-$4MN/AN/A Is PMCB or MYMD more profitable? PharmaCyte Biotech's return on equity of 0.76% beat MyMD Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets PharmaCyte BiotechN/A 0.76% 0.45% MyMD Pharmaceuticals N/A -179.05%-108.14% Do institutionals & insiders hold more shares of PMCB or MYMD? 34.2% of PharmaCyte Biotech shares are owned by institutional investors. Comparatively, 9.6% of MyMD Pharmaceuticals shares are owned by institutional investors. 7.3% of PharmaCyte Biotech shares are owned by company insiders. Comparatively, 2.1% of MyMD Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media refer more to PMCB or MYMD? In the previous week, MyMD Pharmaceuticals had 1 more articles in the media than PharmaCyte Biotech. MarketBeat recorded 1 mentions for MyMD Pharmaceuticals and 0 mentions for PharmaCyte Biotech. PharmaCyte Biotech's average media sentiment score of 1.00 beat MyMD Pharmaceuticals' score of 0.00 indicating that PharmaCyte Biotech is being referred to more favorably in the media. Company Overall Sentiment PharmaCyte Biotech Positive MyMD Pharmaceuticals Neutral Which has more volatility and risk, PMCB or MYMD? PharmaCyte Biotech has a beta of -0.18, meaning that its share price is 118% less volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500. SummaryPharmaCyte Biotech beats MyMD Pharmaceuticals on 6 of the 8 factors compared between the two stocks. Get MyMD Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MYMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYMD vs. The Competition Export to ExcelMetricMyMD PharmaceuticalsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.73M$2.15B$5.70B$9.14BDividend YieldN/A0.69%5.28%4.00%P/E RatioN/A2.6162.8114.83Price / SalesN/A71.70978.6482.89Price / CashN/A16.3437.4433.55Price / Book0.103.465.124.76Net Income-$4M$29.98M$108.98M$223.10M7 Day Performance-37.78%-6.83%0.45%0.18%1 Month Performance-38.82%-13.53%-0.98%-1.98%1 Year Performance-81.33%-17.09%26.67%23.41% MyMD Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYMDMyMD PharmaceuticalsN/A$0.73-17.3%N/A-82.7%$1.73MN/A0.009News CoverageHigh Trading VolumePMCBPharmaCyte Biotech1.917 of 5 stars$1.62-0.9%N/A-30.9%$11.26MN/A3.054Positive NewsCLRBCellectar Biosciences1.7211 of 5 stars$0.27+4.8%$17.67+6,421.5%-93.1%$11.18MN/A-0.1610RLMDRelmada Therapeutics4.5263 of 5 stars$0.37-6.2%$4.25+1,064.4%-92.6%$11.01MN/A-0.1310Gap DownTSBXTurnstone Biologics3.2796 of 5 stars$0.45-2.0%$2.13+371.2%-81.2%$10.64M$19.31M-0.1482News CoverageGap UpPRPHProPhase Labs3.0137 of 5 stars$0.45-17.6%$11.00+2,371.4%-95.3%$10.63M$44.38M-0.35130Gap UpPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049JAGXJaguar Health0.2108 of 5 stars$0.89+3.6%N/A-84.5%$10.50M$9.76M0.0050Gap UpAYTUAytu BioPharma0.9358 of 5 stars$1.70flatN/A-39.8%$10.46M$81M-1.38160Upcoming EarningsShort Interest ↑BCDABioCardia3.7311 of 5 stars$2.27+3.7%$25.00+1,001.3%-59.9%$10.40M$480,000.00-0.5440Gap DownHigh Trading VolumeCSCICOSCIENS BiopharmaN/A$2.71-6.2%N/AN/A$10.24M$4.50M-0.2320Gap Down Related Companies and Tools Related Companies PMCB Alternatives CLRB Alternatives RLMD Alternatives TSBX Alternatives PRPH Alternatives PHXM Alternatives JAGX Alternatives AYTU Alternatives BCDA Alternatives CSCI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MYMD) was last updated on 2/5/2025 by MarketBeat.com Staff From Our PartnersNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNew crypto boom will be greatest in historyUrgent Notice from Ian King, the Crypto Expert Who Made 18,325% in a Year: “Donald Trump’s second term is t...Banyan Hill Publishing | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MyMD Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MyMD Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
